Search

Your search keyword '"Martin JH"' showing total 657 results

Search Constraints

Start Over You searched for: Author "Martin JH" Remove constraint Author: "Martin JH"
657 results on '"Martin JH"'

Search Results

151. Clinical trials with cannabis medicines-guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: considerations from the Australian experience.

152. Molecular insights into the divergence and diversity of post-testicular maturation strategies.

153. Translational hurdles with cannabis medicines.

154. Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis.

155. Frequency distribution in intraoperative stimulation-evoked EMG responses during selective dorsal rhizotomy in children with cerebral palsy-part 2: gender differences and left-biased asymmetry.

156. Frequency distribution in intraoperative stimulation-evoked EMG responses during selective dorsal rhizotomy in children with cerebral palsy-part 1: clinical setting and neurophysiological procedure.

158. Buying time: Drug repurposing to treat the host in COVID-19H.

159. Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes.

160. Semaphorin-Mediated Corticospinal Axon Elimination Depends on the Activity-Induced Bax/Bak-Caspase Pathway.

161. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.

163. Vancomycin: Audit of American guideline-based intermittent dose administration with focus on overweight patients.

165. Vancomycin therapeutic drug monitoring in paediatrics.

167. Reproductive health research in Australia and New Zealand: highlights from the Annual Meeting of the Society for Reproductive Biology, 2019.

168. Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies.

169. "I'm a Survivor": Aboriginal and Torres Strait Islander Cancer Survivors' Perspectives of Cancer Survivorship.

170. Barriers and Challenges in Performing Pharmacokinetic Studies to Inform Dosing in the Neonatal Population.

171. Using Therapeutic Drug Monitoring and Pharmacovigilance to Overcome Some of the Challenges of Developing Medicinal Cannabis from Botanical Origins.

173. Dominant-negative SOX9 mutations in campomelic dysplasia.

174. The Quasi-uniform assumption for Spinal Cord Stimulation translational research.

176. Whole-body exposures to radiofrequency-electromagnetic energy can cause DNA damage in mouse spermatozoa via an oxidative mechanism.

177. Neuronal activity and microglial activation support corticospinal tract and proprioceptive afferent sprouting in spinal circuits after a corticospinal system lesion.

178. Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50.

179. Optimising low-dose methotrexate for rheumatoid arthritis-A review.

180. Independent replication of motor cortex and cervical spinal cord electrical stimulation to promote forelimb motor function after spinal cord injury in rats.

182. The rationale of dose-response curves in selecting cancer drug dosing.

186. Reply.

187. Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles.

188. Investigation into the presence and functional significance of proinsulin C-peptide in the female germline†.

189. Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention.

190. Modification of Crocodile Spermatozoa Refutes the Tenet That Post-testicular Sperm Maturation Is Restricted To Mammals.

191. DNA damage and repair in the female germline: contributions to ART.

192. Diving, cannabis use, and techniques of neutralisation: exploring how divers rationalise cannabis use.

193. Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects.

194. Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.

196. Transneuronal Downregulation of the Premotor Cholinergic System After Corticospinal Tract Loss.

197. The PTH/PTHrP-SIK3 pathway affects skeletogenesis through altered mTOR signaling.

198. Cannabinoid Disposition After Human Intraperitoneal Use: AnInsight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer.

199. Stimulation-dependent remodeling of the corticospinal tract requires reactivation of growth-promoting developmental signaling pathways.

Catalog

Books, media, physical & digital resources